There's new data regarding rare cases of blood clotting in COVID-19 patients and vaccine recipients; CBS2's Dr. Max Gomez reports.
- There is new data tonight over those rare cases of blood clotting in COVID patients and vaccine recipients. CBS 2's Dr. Max Gomez with more on the research.
MAX GOMEZ: Extremely rare blood clots after the Johnson & Johnson COVID-19 vaccine led US health officials to pause the use of that vaccine. Now new research from Oxford University in England finds the risk of cerebral venous thrombosis or CVT is 8 to 10 times higher after COVID-19 infection than from the vaccine's meant to protect against the virus.
JOHN GEDDES: The importance this finds it brings it back to the fact that this is a really horrible illness. It has a whole variety of effects, including an increased risk of CVT and PVT in this group.
MAX GOMEZ: The AstraZeneca vaccine, co-developed by Oxford University, has also been linked to rare blood clots in the UK. The Oxford study, which hasn't yet been reviewed by scientists or published, looked at 500,000 COVID-19 patients and found CVT occurred at a rate of 39 in a million people after infection. Those numbers were four in a million with the Pfizer or Moderna vaccines and five in a million with the AstraZeneca vaccine. But US researchers say there are significant problems with the data analysis and the paper that led to unsupported conclusions.
ANTHONY FAUCI: You cannot make any statement the way this is designed about the adverse events following the vaccination with the mRNA comparing to anything else. There were many, many, I would say, procedural gaps in here regarding the way the study was done.
MAX GOMEZ: The numbers in the Oxford study are also at odds with the data that the CDC's advisory committee considered yesterday in extending the J&J pause. The important conclusion though, is that the benefits of vaccination still far outweigh the risks of getting COVID. Dr. Max Gomez, CBS 2 News.